Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
Thompson, Philip J.; Criner, Gerard J.; Dransfield, Mark T.; Halpin, David M. G.; Han, MeiLan K.; Lipson, David A.; Maghzal, Ghassan J.; Martinez, Fernando J.; Midwinter, Dawn; Singh, Dave; Tombs, Lee; Wise, Robert A.
2022-12
Citation
Thompson, Philip J.; Criner, Gerard J.; Dransfield, Mark T.; Halpin, David M. G.; Han, MeiLan K.; Lipson, David A.; Maghzal, Ghassan J.; Martinez, Fernando J.; Midwinter, Dawn; Singh, Dave; Tombs, Lee; Wise, Robert A. (2022). "Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial." Respirology 27(12): 1034-1044.
Abstract
Background and objectiveChronic mucus hypersecretion (CMH) is a clinical phenotype of COPD. This exploratory post hoc analysis assessed relationship between CMH status and treatment response in IMPACT.MethodsPatients were randomized to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg, FF/VI 100/25 μg or UMEC/VI 62.5/25 μg and designated CMH+ if they scored 1/2 in St George’s Respiratory Questionnaire (SGRQ) questions 1 and 2. Endpoints assessed by baseline CMH status included on-treatment exacerbation rates, change from baseline in trough forced expiratory volume in 1 second, SGRQ total score, COPD Assessment Test (CAT) score, proportion of SGRQ and CAT responders at Week 52 and safety.ResultsOf 10,355 patients in the intent-to-treat population, 10,250 reported baseline SGRQ data (CMH+: 62% [n = 6383]). FF/UMEC/VI significantly (p < 0.001) reduced on-treatment moderate/severe exacerbation rates versus FF/VI and UMEC/VI in CMH+ (rate ratio: 0.87 and 0.72) and CMH− patients (0.82 and 0.80). FF/UMEC/VI significantly (p < 0.05) reduced on-treatment severe exacerbation rates versus UMEC/VI in CMH+ (0.62) and CMH− (0.74) subgroups. Similar improvements in health status and lung function with FF/UMEC/VI were observed, regardless of CMH status. In CMH+ patients, FF/VI significantly (p < 0.001) reduced on-treatment moderate/severe and severe exacerbation rates versus UMEC/VI (0.83 and 0.70).ConclusionFF/UMEC/VI had a favourable benefit: risk profile versus dual therapies irrespective of CMH status. The presence of CMH did not influence treatment response or exacerbations, lung function and/or health status. However, CMH did generate differences when dual therapies were compared and the impact of CMH should be considered in future trial design.The relationship between chronic mucus hypersecretion (CMH) and treatment response to FF/UMEC/VI, FF/VI or UMEC/VI was assessed in symptomatic patients with COPD and a history of exacerbations. FF/UMEC/VI reduced exacerbation rates versus FF/VI and UMEC/VI irrespective of CMH status; similar improvements in health status and lung function were observed.See related EditorialPublisher
John Wiley & Sons, Ltd
ISSN
1323-7799 1440-1843
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.